Role of Tirzepatide in Obesity Management Among Women with Polycystic Ovary Syndrome
Bibliographic record
Abstract
Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women, often associated with obesity, insulin resistance, and metabolic complications. Managing weight is crucial for improving PCOS symptoms and overall health. This study aimed to evaluate the effectiveness of Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, in obesity management and symptom improvement among women with PCOS. Methods: This retrospective observational study was conducted in the Department of Cardiology, Uttara Adhunik Medical College Hospital, LabAid Cancer Hospital & Super Speciality Centre, LabAid Diagnostics Center, Uttara, Dhaka, Bangladesh, from July 2024 to February 2025. In this study, we included 56 women with polycystic ovary syndrome associated with obesity who were referred to a consultant gynecologist or cardiologist for menstrual problems, obesity, and hypertension. Result: In this study, we found that after treatment, there was a significant weight reduction of 9.54% (p = 0.0004), with BMI decreasing from 36.51 ± 6.14 to 32.49 ± 4.68 kg/m² (p = 0.0002). Glycemic control improved significantly, with fasting blood sugar dropping from 6.89 ± 0.78 mg/dl to 5.57 ± 0.42 mg/dl (p < 0.0001) and HbA1c decreased from 5.7 ± 0.6% to 4.9 ± 0.4% (p < 0.0001). PCOS symptoms showed remarkable improvement, with irregular menstrual cycles decreased from 85.7% to 32.1% (p < 0.0001), and ovarian cyst prevalence dropped from 89.3% to 41% (p < 0.0001). Insulin resistance improved significantly (80.4% to 50%, p = 0.0008). The most common side effects were heartburn (42.86%), nausea/vomiting (39.29%), and general weakness (33.93%). Conclusion: In this study, Tirzepatide showed promising results in managing obesity and improving metabolic outcomes in women with PCOS. Significant weight reduction, glycemic control, and symptom improvement were observed in our study patients. Our study suggests that Tirzepatide could be a valuable therapeutic option for obese women with PCOS.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".